Follows people with movement disorders treated with deep brain stimulation devices
Studies long-term safety of brain stimulation devices in people with Parkinson disease, tremor, or dystonia.
Plain-language title generated from the registry record
Registry title: Abbott DBS Post-Market Study of Outcomes for Indications Over Time
Key facts
- Where
- Badalona, Madrid, and Seville, SpainSee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who are about to have a new Abbott deep brain stimulation (DBS) device implanted, or an existing device battery (IPG) replaced.
- Sex
- All sexes can join.
- Earlier treatment
- Surgery with a market-released Abbott DBS system must be planned within 180 days.
Main reasons for not taking part
- Taking part in another investigational study that could affect the results
- Medical, social or psychological conditions that, in the investigator's opinion, limit taking part or follow-up
- In US centers: DBS not for Parkinson's disease or disabling tremor
- In US centers: lead not placed at or near the STN, GPi or VIM thalamus
Read by machine on 9 November 2026.
Where in Spain
- Hospital Universitari Germans Trias i PujolBadalona, SpainTaking people
- Hospital Universitario de la PrincesaMadrid, SpainTaking people
- Hospital Virgen de RocioSeville, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Abbott Medical Devices
- Trial code
- NCT04071847
- Record updated
- 8 January 2026
- Original description
The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.Read full original descriptionShow less
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.
Inclusion: Subject is scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 180 days; Subject, or a legally acceptable representative, must provide written informed consent prior to any study-related procedure.
Exclusion: Study center is located in the United States, and the intended lead implant location is not at, or in close proximity to, the STN, GPi, or VIM thalamus; Subject has anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results; Study center is located in the United States, and indication for DBS implant is not Parkinson's disease or disabling tremor; Subject is currently enrolled or plans to enroll in an investigational study that may confound the results of this study.